Advocates urge J&J to ‘put everything on the table’ for gene therapy despite failed trialnews2025-07-01T14:48:52+00:00July 1st, 2025|Endpoints News|
CEOs push EU for cell, gene therapy incentives in Biotech Actnews2025-06-27T16:22:05+00:00June 27th, 2025|Endpoints News|
Bayer’s BlueRock prioritizes neurology, eye programs, lays off about 50 staffersnews2025-06-25T14:14:15+00:00June 25th, 2025|Endpoints News|
FDA investigating Sarepta’s Duchenne gene therapy following patient deathsnews2025-06-25T07:56:00+00:00June 25th, 2025|Endpoints News|
#ADA25: Vertex’s diabetes cell therapy allows 10 patients to come off insulinnews2025-06-20T23:15:41+00:00June 20th, 2025|Endpoints News|
BioNTech drops indications, stops making cell therapy at Maryland sitenews2025-06-18T15:25:03+00:00June 18th, 2025|Endpoints News|
#EHA25: Gilead, Arcellx continue to tout safety of multiple myeloma cell therapy anito-celnews2025-06-16T08:48:16+00:00June 16th, 2025|Endpoints News|
Sarepta halts Duchenne gene therapy in some patients after second deathnews2025-06-16T02:18:20+00:00June 16th, 2025|Endpoints News|
SpliceBio gets $135M shortly after starting first clinical trialnews2025-06-11T07:00:58+00:00June 11th, 2025|Endpoints News|
Vertex lays off 125 workers after type 1 diabetes cell therapy failed study in Marchnews2025-06-11T01:06:41+00:00June 11th, 2025|Endpoints News|
